We describe our experience with intravenous amoxicillin-clavulanate, which is new to the Canadian market. The majority of patients were successfully de-escalated from piperacillin-tazobactam or a carbapenem for respiratory infections or skin and soft tissue infections. Intravenous amoxicillin-clavulanate provides a good alternative in an era of rising resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10897708 | PMC |
| http://dx.doi.org/10.1017/ash.2024.18 | DOI Listing |
Publication Analysis
Top Keywords
intravenous amoxicillin-clavulanate
12
amoxicillin-clavulanate canadian
8
evaluation intravenous
4
canadian hospitals
4
hospitals describe
4
describe experience
4
experience intravenous
4
canadian market
4
market majority
4
majority patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!